347 Results

FDA accepts sBLA for Tecentriq + Abraxane + carboplatin to treat metastatic NSCLC patients who do not have EGFR or ALK genomic tumor aberrations. Genentech/Roche

 Added 6 days ago

Genentech, a member of the Roche Group announced that the FDA has accepted the company’s supplemental Biologics License Application (sBLA)...

FDA extends sBLA for Keytruda as a treatment for first line NSCLC.- Merck Inc.

 Added 1 month ago

Merck Inc., announced that the FDA has extended the action date for the supplemental Biologics License Application (sBLA) for Keytruda,...

New analysis of MYSTIC trial of Imfinzi monotherapy or Imfinzi + tremelimumab was presented at the ESMO Immuno-Oncology Congress- AstraZeneca

 Added 1 month ago

In a full analysis of the MYSTIC study of Imfinzi (durvalumab) monotherapy or Imfinzi + tremelimumab which was presented at...

CHMP recommends approval of Zirabev (bevacizumab biosimilar) for metastatic cancer.- Pfizer.

 Added 1 month ago

Pfizer announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency (EMA) has adopted a...

FDA approves Tecentriq + Avastin for the initial (first-line) treatment of people with metastatic NSCLC with no EGFR or ALK genomic tumor aberrations. Genentech/Roche.

 Added 1 month ago

Genentech, a member of the Roche Group announced that the FDA approved Tecentriq (atezolizumab), in combination with Avastin (bevacizumab), paclitaxel...

AbbVie stops enrollment in TAHOE trial of Rova-T to treat small cell lung cancer.

 Added 1 month ago

AbbVie announced the decision to stop enrollment for the TAHOE trial a Phase III study evaluating Rovalpituzumab Tesirine (Rova-T) as...

FDA accepts BLA and provides priority review for Tecentriq to treat small cell lung cancer- Genentech/Roche

 Added 1 month ago

Genentech has announced that the FDA has accepted the company’s supplemental Biologics License Application (sBLA) and granted Priority Review for...

Opdivo + Yervoy combination fails to meet primary endpoint in CHECKMATE 451 trial to treat small cell lung cancer.- BMS

 Added 1 month ago

Bristol-Myers Squibb Company announced that the Phase III CheckMate -451 study did not meet its primary endpoint of overall survival...

AstraZeneca provides update on the Phase III MYSTIC trial of Imfinzi and tremelimumab in Stage IV NSCLC.

 Added 2 months ago

AstraZeneca and MedImmune, its global biologics research and development arm, announced final overall survival (OS) results for the Phase III...

FDA gives accelerated approval to Lorbrena for ALK-positive metastatic non-small cell lung cancer.- Pfizer.

 Added 2 months ago

Pfizer announced that the FDA has approved Lorbrena (lorlatinib), a third-generation anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitor (TKI) for...

Load more